- Home
- SHBI vs GOSS Comparison
SHBI vs GOSS Comparison
Compare SHBI & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHBI | GOSS |
|---|---|---|
| Founded | 1876 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 601.1M | 615.7M |
| IPO Year | 1997 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SHBI | GOSS |
|---|---|---|
| Price | $17.75 | $0.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $19.17 | $4.91 |
| AVG Volume (30 Days) | 172.4K | ★ 26.4M |
| Earning Date | 04-29-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.67% | N/A |
| EPS Growth | 34.85 | ★ 78.81 |
| EPS | ★ 1.78 | N/A |
| Revenue | $20,853,000.00 | ★ $114,701,000.00 |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $6.71 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.47 | $0.33 |
| 52 Week High | $20.68 | $3.87 |
Technical Indicators
Market Signals| Indicator | SHBI | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 23.01 |
| Support Level | $17.14 | $0.33 |
| Resistance Level | $19.31 | $0.60 |
| Average True Range (ATR) | 0.57 | 0.08 |
| MACD | -0.19 | 0.01 |
| Stochastic Oscillator | 17.17 | 9.07 |
Price Performance
Historical ComparisonAbout SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.